Mucormycosis is a rare type of fungal infection that, if left untreated, can be lethal. It’s found in a variety of places, including soil, manure, plants, and decaying vegetables and fruits. It affects the sinuses, lungs, and brain. This infection can be fatal in diabetic patients or persons who are extremely immunocompromised such as cancer patients and HIV/AIDS patients. Mucormycosis is a life-threatening invasive fungal illness that has a high rate of morbidity and mortality despite treatment.
It primarily affects immunocompromised people who have undergone bone marrow and organ transplantation. Moreover, it spreads among individuals who have cancer, neutropenia, and skin damage. Immunocompetent patients are occasionally affected. Mucormycosis is a fungal infection caused by a group of molds known as mucormycosis. Mold spores can irritate the lungs and sinuses, and the fungus can enter the skin through wounds such as cuts, scrapes, burns, and other types of skin trauma. Mucormycosis lead to organ dysfunctions, blindness, and other problems requiring surgical treatments.
Immunological Disease Cases Increasing at a Higher Rate
Increased occurrence of fungal infections, rise in prevalence of immunological illnesses, and improved access to a wide range of products are driving the mucormycosis market. Furthermore, growing public awareness of fungal infection and increasing government assistance for R&D have fueled the market expansion. The global market for mucormycosis diagnosis and treatment will develop as the diabetic population grows and the number of transplant procedures rises. The size and frequency of mucormycosis prevalent during the second wave of the pandemic is posing a problem for doctors and other healthcare workers.
Asia Pacific Region Projected to Account for Largest Revenue Share
The key factor driving the mucormycosis market in Europe, where the average diabetes prevalence rate in adults is increasing, is an expanding patient population of diabetes mellitus patients. Another major driver of market rapid expansion is favorable government initiatives aimed at boosting the anti-infective medication while lowering risk and manufacturing costs. The European Confederation of Medical Mycology (ECMM) has taken the lead in developing a global guideline for mucormycosis diagnosis and treatment.
The market in the Asia Pacific is predicted to grow rapidly in the coming years. The rising prevalence of HIV and the potential for establishing efficient diagnostics in underdeveloped emerging nations are creating major development opportunities. India is witnessing a burden of mucormycosis infection as a result of the COVID-19 outbreak. On the other hand, the difficulty of gaining market access will continue to be a major impediment to market growth in Asia.
Key Players with Dominant Position in the Mucormycosis Market
VAV Life Sciences has announced the company’s plan to increase the capacity to develop highly purified synthetic lipids. These are required primarily to produce Amphotericin B, which is used as a drug to treat fungal diseases such as mucormycosis. Leading market participants are Gilead Sciences, F. Hoffman La Roche, Bristol Myers Squibb, Biocon Limited, Pfizer Inc., Johnson & Johnson, Abbott Laboratories, and Mylan Labs. These companies have a major challenge in front of them to come up with effective solutions to contain the spread of mucormycosis.
Deep-dive Insights on Mucormycosis Market by Polaris Market Research: https://www.polarismarketresearch.com/industry-analysis/mucormycosis-market/request-for-sample